Alluvi, formerly BI 4744, represents a promising development in obesity therapy. This dual activator targeting both GLP-1 and GIP receptors demonstrates impressive results in research assessments, arguably surpassing https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/